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Abstract The purpose of this study was to explore the
prevalence and nature of cardiac abnormalities in sporadic
inclusion body myositis (sIBM). Fifty-one sIBM patients
were cross-sectionally studied using history-taking, physi-
cal examination, measurements of serum creatine kinase
activity, the MB fraction (CK-MB), cardiac troponin T
(cTnT) and I (cTnI), a 12-lead electrocardiogram (ECG)
and 2-dimensional echocardiography. Present cardiac his-
tory was abnormal in 12 (24%) out of 51 patients, 12 (24%)
patients had abnormalities on ECG, mostly aspeciﬁc, and
in 12 (24%) patients the echocardiograph showed abnor-
malities. Elevated CK-MB was present in 42 (82%)
patients and 40 (78%) had an elevated cTnT in the absence
of acute cardiac pathology. In contrast, in one patient (2%)
cTnI was elevated. There was no apparent association
between elevated biomarkers, ECG or echocardiographic
abnormalities. The prevalence of cardiac abnormalities in
sIBM does not seem to be higher than would be expected in
these elderly patients. Elevated CK-MB and cTnT levels
are common, in contrast to cTnI, but do not reﬂect cardiac
pathology.
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Introduction
Sporadic inclusion body myositis (sIBM) is a slowly pro-
gressive inﬂammatory myopathy of striated skeletal mus-
cle, particularly affecting the quadriceps muscles, forearm
ﬂexors and pharyngeal muscles. Symptoms usually occur
after the age of forty [4, 20].
Muscle biopsy specimens show predominantly endo-
mysial inﬂammation, with CD8? T-cells invading non-
necrotic muscle ﬁbers. These inﬁltrates resemble those in
polymyositis (PM). Essential differences with PM are the
presence of rimmed vacuoles and intracellular deposits of a
host of proteins, including b-amyloid and hyperphospho-
rylated tau in sIBM.
Cardiovascular studies in PM and dermatomyositis
(DM), cross-sectional or retrospective, reported abnor-
malities in 32.5–85% of the patients, comprising conges-
tive heart failure, conduction abnormalities, myocarditis,
arrhythmias and cardiomyopathy [13, 14, 21, 26]. At the
time these studies were done, sIBM was not yet considered
a distinct disease entity, and the Bohan and Peter criteria
then used resulted in the inclusion of sIBM patients into the
PM groups [8, 9]. Cardiovascular case series in sIBM have
not been published as far as we know.
The present study explored the possible involvement
of the heart in sIBM patients using non-invasive
techniques.
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Study population
The study comprised 51 patients diagnosed with sIBM,
selected from a national cohort of 86 sIBM patients. The
recruitment procedure has been previously described in
detail [3]. In short, a database of sIBM patients was started
through a national survey in all large neurologic and
rheumatologic centers in the Netherlands in order to
identify as many sIBM patients as possible. Clinical data
and biopsy specimens of all patients previously coded with
a diagnosis of sIBM, a chronic or refractory myositis or
progressive myopathy of unknown origin, with an onset
after the age of 45 years were reevaluated for sIBM char-
acteristics. Included patients fulﬁlled the ENMC criteria for
deﬁnite or probable sIBM [28]. The study protocol inclu-
ded a cross-sectional clinical evaluation, blood sample
analysis, 12-lead electrocardiography (ECG) and trans-
thoracic echocardiography. The studies were done at Lei-
den University Medical Center after approval by the Ethics
committee and after attaining informed consent of all
patients. From the remaining 35 patients who were not
included in the present study, 13 refrained from partici-
pation, 5 could not be located, 6 died before starting the
protocol (1 patient due to adenocarcinoma of the lung, one
due to gastric bleeding, and 4 to causes unknown) and 11
did not undergo cardiac evaluation due to logistic
difﬁculties.
Clinical evaluation
History-taking focussed on the presence of cardiovascular
risk factors and previous history of ischemic heart disease,
heart failure, cardiac arrhythmias and pericardial disease.
The physical examination comprised 12 automated
blood pressure and pulse rate measurements taken within
30 min while seated, and a heart examination.
Blood sample analysis
Serum creatine kinase activity (sCK), the MB fraction
(CK-MB) and cardiac Troponin T (cTnT) and Troponin I
(cTnI) were analyzed. Normal values for sCK were
B170 U/L in women and B200 U/L in men and for CK-
MB B 10 lg/L. The cut off value for cTnT was 0.03 lg/L
and for cTnI[0.2 lg/L.
Electrocardiography
The presence of any conduction disturbance, arrhythmia,
myocardial ischemia or infarction was evaluated by ECG
(25 mm/s) as follows: heart rhythm was classiﬁed as sinus
rhythm, atrial ﬁbrillation or ﬂutter, or paced rhythm. A
QRS axis between -30 and -90 indicated a left axis
deviation, an axis between ?90 and ?180 indicated right
axis deviation [17]. Complete bundle branch block (BBB)
was deﬁned by a QRS complex duration of [120 ms.
Extrasystolic beats, sinus bradycardia (\60 beats/min) and
-tachycardia ([100 beats/min) were noted.
ST-segment depression [1 mm and abnormal negative
T-waves in two consecutive leads suggested myocardial
ischemia. Pathological Q-waves in at least two consecutive
leads, with a duration[0.04 s and a depth[25% of the R-
wave voltage, indicated previous myocardial infarction.
Left ventricular (LV) hypertrophy was assessed using
the Sokolow index [24]. The corrected QT-interval (QTc)
was calculated according to Bazett’s formula [5].
Echocardiography
Patients were imaged in the left lateral decubitus position
using a commercially available system (Vingmed system
Vivid-5; General Electric-Vingmed, Milwaukee, WI,
USA). Standard 2-dimensional and color Doppler data,
triggered to the QRS complex, were obtained using a
3.5 MHz transducer, at a depth of 16 cm in the parasternal
(long- and short-axis) and apical (2- and 4-chamber, long-
axis) views. The images were stored for off-line analysis
(EchoPac 6.0.1, General Electric Vingmed Ultrasound,
Milwaukee, USA).
Both ECG and echocardiography were analyzed by one
independent cardiologist blinded with regard to the clinical
status of the patient, but aware of the sIBM diagnosis.
LV dimensions and function were measured from M-
mode images. LV wall motion was classiﬁed as abnormal
when hypokinesia was observed. LV mass was calculated
by the cube formula and using the correction formula
proposed by Devereux et al. [10]. LV mass index (LVMI)
was calculated after correction for body surface area. A
value of LVMI[110 g/m
2 in women and [135 g/m
2 in
men deﬁned LV hypertrophy [27].
LV diastolic function was evaluated by the pulsed wave
Doppler recordings of the transmitral inﬂow velocity [22].
Diastolic transmitral peak velocities (E-wave and A-wave),
the E/A ratio and the E-deceleration time were measured.
Valvular function was evaluated with color Doppler
echocardiography and standard continuous and pulsed
wave Doppler examinations.
Statistical analysis
Continuous variables were compared using the Mann–
Whitney U test. Categorical variables were compared using
the Fisher exact test. Laboratory data are stated as median
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123(range), other data are presented as mean ± standard
deviation.
Results
Study population and clinical evaluation
All 51 sIBM patients (67 ± 9 years, 34 men) completed the
study protocol. Mean disease duration was 11 ± 6 years.
The investigated group did not differ signiﬁcantly from the
original population group of 86 patients with regard to sex
distribution, age (at onset) and disease duration. The car-
diovascular history proﬁle up to inclusion is summarized in
Table 1.
The majority of the patients (n = 39, 76%) reported no
cardiovascular symptoms at the time of history taking. The
remaining 12 patients (24%) disclosed exertion-induced
chest pain, dyspnea, nycturia or palpitations. None of the
patients had had a myocardial infarction within 3 months
prior to evaluation. The mean systolic and diastolic blood
pressures at examination were 133 ± 19 and 77 ± 12
respectively. A cardiac murmur was noted in 7 (14%)
patients.
Laboratory data
Elevated sCK levels were observed in 42 (82%) patients,
506 U/L (64–3,360) in men, 246 U/L (44–802) in women.
Elevated CK-MB levels were measured in 42 (82%)
patients, 18 lg/L (2–124). Elevated cTnT levels were
observed in 40 (78%) patients, 0.08 lg/L (0.01–0.99), and
an elevated cTnI level of 0.22 lg/L was found in one
patient. CK-MB was elevated in four patients with a nor-
mal sCK.
Electrocardiographic data
Most patients were in sinus rhythm (n = 47, 92%). Three
(6%) patients had atrial ﬁbrillation and 1 (2%) a paced
rhythm. Mean heart rate was 69 ± 15 beats/min.
The mean QRS duration was 91 ± 20 ms. Thirty-four
(67%) patients showed a normal QRS axis, 2 (4%) a right
axis deviation and 13 (25%) a left axis deviation. Two
(4%) patients had complete BBB whereas 5 (10%)
patients had incomplete BBB. Seven (14%) patients had
signs of previous myocardial infarction whereas 4 (8%)
had signs corresponding to our deﬁnition of myocardial
ischemia.
Nine (18%) patients had LV hypertrophy. Mean QTc
duration was normal.
Echocardiographic data
Most patients had a non-dilated LV with preserved func-
tion. Impaired systolic function (LV ejection fraction
\50%) was observed in 4 (8%) patients. Fourteen (27%)
patients met the echocardiographic criteria of LV hyper-
trophy. The LV diastolic function could be reliably asses-
sed in 45 patients. The mean E/A ratio was 0.9 ± 0.6,
which is in the normal range above the age of ﬁfty.
The majority of the patients had normal valvular func-
tion. Mild mitral (n = 7, 14%), aortic (n = 8, 16%), and
tricuspid (n = 7, 14%) regurgitation were infrequently
found and only 1 (2%) patient had moderate tricuspid
regurgitation.
Myocardial damage evaluation by combining serum
levels of cardiac biomarkers, ECG and
echocardiographic ﬁndings
To evaluate the clinical signiﬁcance of the raised bio-
markers, we compared the values of biomarkers between
patients with and without abnormalities on ECG and
echocardiography. For this purpose, pathologic ECG
(n = 12, 24%) was deﬁned by the presence of any con-
duction abnormality, pathologic ST-segment depression or
Table 1 Cardiovascular proﬁle
Cardiovascular risk factors
Hypertension 12 (24%)
Hypercholesterolemia 1 (2%)
Diabetes mellitus 1 (2%)
Obesity (BMI[30 kg/m
2) 5 (10%)
Cigarette smoking
Present 5 (10%)
Previous 15 (29%)
Previous cardiac history
Myocardial infarction 8 (16%)
Coronary revascularisation 3 (6%)
Conduction abnormalities 5 (10%)
Requiring pacemaker 2 (4%)
Pericarditis 1 (2%)
Heart failure 1 (2%)
Mitral valve abnormalities 2 (4%)
Requiring valve replacement 1 (2%)
Cardiovascular medications
b-blockers 10 (20%)
Calcium-antagonists 4 (8%)
ACE-inhibitors 7 (14%)
Diuretics 8 (16%)
Multiple items possible per patient
BMI body mass index, ACE-inhibitors angiotensin converting enzyme
inhibitors
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123pathologic Q waves, whereas pathologic echocardiography
(n = 12, 24%) was deﬁned by the presence of impaired
systolic LV function or wall motion abnormalities.
Of the patients with a normal ECG or echocardiogra-
phy, 79% had raised CK-MB levels versus 100% in
patients with a pathologic ECG or echocardiography
(p = 0.2). For cTnT, these numbers were 79 and 85%
respectively (p = 0.8). CK-MB and cTnT levels did not
differ between the groups with and without pathologic
ECG or echocardiography either (p = 0.8 and 0.09,
respectively).
The only patient with an elevated cTnI had pathologic
ﬁndings on ECG and echocardiography, including a wall
motion abnormality with an ejection fraction of 18%.
Thus, raised cardiac biomarkers were not associated
with pathologic ﬁndings on ECG or echocardiography and,
furthermore, the majority of the patients with raised cardiac
biomarkers had a normal ECG or echocardiography.
Discussion
The present study showed that the vast majority of sIBM
patients were asymptomatic with regard to cardiac symp-
toms at the time of investigation. The frequencies of ECG
and echocardiography abnormalities approximate those
from large epidemiological studies in several cohorts from
general populations with a similar age distribution as the
present study [2, 11, 16, 25]. Therefore, the prevalence and
nature of the found abnormalities are considered to be
unrelated to sIBM. Consequently, standard cardiac evalu-
ation in sIBM is not considered mandatory. This is dif-
ferent from previous ﬁndings in polymyositis and
dermatomyositis.
In the last decade, cardiac troponins (cTnT or cTnI)
have emerged as more speciﬁc biomarkers of cardiac
damage as compared to sCK or CK-MB, and particularly
acute myocardial ischemia is based upon raised troponin
levels [15, 29]. Elevation of cTnT has been described in
PM, DM and sIBM patients without apparent cardiac
ischemia [12, 19]. In addition, one study and one case
report described normal cTnI levels in the presence of
elevated cTnT in myositis [12, 23]. In contrast to the
present study, possible cardiac involvement was not stud-
ied by ECG, nor by echocardiography.
It has been hypothesized that CK-MB and cTnT, both
expressed in fetal muscle, but down-regulated during
development, are re-expressed in regenerating muscle
ﬁbers [7, 18, 19]. These ﬁbers are common in PM, DM and
sIBM muscle biopsies. Consequently, CK-MB and cTnT
elevations arise in the absence of cardiac ischemia. Con-
trarily, cTnI, exclusively expressed in cardiac muscle,
remains normal [6].
In the present study, CK-MB and cTnT were commonly
elevated in the absence of cardiac pathology. The only
patient with an elevated cTnI had a severe cardiomyopathy,
explaining this elevation [1]. These outcomes support the
hypothesis that elevated CK-MB and cTnT levels in sIBM
are not of cardiac origin, but originate from skeletal muscle
tissue.
The present study does not show evidence for cardiac
involvement in sIBM, and therefore we do not recommend
routine comprehensive cardiac evaluation in sIBM patients
without cardiac symptoms. Increased cardiac biomarkers,
i.e., CK-MB and cTnT in sIBM, do not necessarily suggest
cardiac damage. To detect cardiac ischemia in sIBM
patients, cTnI is likely the most informative and recom-
mended biomarker.
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